Characterising the protein signatures in tumours following vascular-targeted therapy will help determine both treatment response and resistance mechanisms. Here, mass spectrometry imaging and MS/MS with and without ion mobility separation have been used for this purpose... View more
1) Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell. 100. 57- 70
2) Lord CJ and Ashworth A (2010) Biology-driven cancer drug development: back to the future. BMC Biology. 8. (38) 1-12
3) Kanthou and Tozer (2007) Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton. Drug discovery today: Therapeutic strategies. 4. (4) 237-243
4) Thorpe PE, Chaplin DJ, Blakey DC (2003) The first international conference on vascular targeting: Meeting overview. Cancer Research. 63. 1144-1147
5) Zhi-chao SI, Jie L (2008) What 'helps' tumours evade vascular targeting treatment? Chinese Medical Journal. 121. (9) 844-849
6) Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill A (2008) Tumour vascular disrupting agents: combating treatment resistance. The British Journal of Radiology. 81. S12-S20
7) Abdollahi A, Folkman J (2010) Evading tumour evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resistance Updates. 13. 16-28
8) Kanthou C and Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies International Journal of Experimental Pathology 80. 284-294.
9) Siemann W. (2009) "Vascular targeted therapies in oncology" Cell and Tissue Research 335. 241-248.
10) Caprioli, R. M., Farmer T.B. and Gile J. (1997) Molecular Imaging of Biological Samples: Localization of Peptides and Proteins Using MALDI-TOF MS Anal. Chem. 69, 4751-4760.